Relationship of treatment response with proportion of patients with high mean tumor cell HLA class I scores in metastases (χ2 test)
| HLA Class I Ab | CR+PR+ SD >6 months | PD+ SD ≤6 months | P value | CR+PR | PD+SD | P value |
| Lymph node metastases (no of patients: 19) | ||||||
| HC10 | 5/6 (83%) | 5/13 (38%) | 0.0686 | 4/4 (100%) | 6/15 (40%) | 0.0327 |
| HCA2* | 4/5 (80%) | 6/12 (50%) | 0.2521 | 3/3 (100%) | 7/14 (50%) | 0.1103 |
| EMR8-5 | 6/6 (100%) | 6/13 (46%) | 0.0237 | 4/4 (100%) | 8/15 (53%) | 0.0856 |
| β2M | 5/6 (83%) | 5/13 (38%) | 0.0686 | 3/4 (75%) | 7/15 (47%) | 0.3133 |
| Low expression with ≤1 Abs | 5/6 (83%) | 5/13 (38%) | 0.0686 | 4/4 (100%) | 6/15 (40%) | 0.0327 |
| Cutaneous/subcutaneous metastases (no of patients: 20) | ||||||
| HC10 | 6/8 (75%) | 7/12 (58%) | 0.4439 | 3/4 (75%) | 10/16 (62%) | 0.6392 |
| HCA2 | 5/8 (62%) | 6/12 (50%) | 0.5820 | 3/4 (75%) | 8/16 (50%) | 0.3687 |
| EMR8-5 | 5/8 (62%) | 7/12 (58%) | 0.8522 | 4/4 (100%) | 8/16 (50%) | 0.0679 |
| β2M | 6/8 (75%) | 8/12 (67%) | 0.6903 | 4/4 (100%) | 10/16 (62%) | 0.1432 |
| Low expression with ≤1 Abs | 5/8 (62%) | 5/12 (42%) | 0.3613 | 4/4 (100%) | 6/16 (37%) | 0.0253 |
| All cases (no of patients: 30) | ||||||
| HC10 | 8/11 (73%) | 9/19 (47%) | 0.1768 | 5/6 (83%) | 12/24 (50%) | 0.1405 |
| HCA2* | 6/10 (60%) | 7/18 (39%) | 0.2831 | 4/5 (80%) | 9/23 (39%) | 0.0968 |
| EMR8-5 | 8/11 (73%) | 9/19 (47%) | 0.1768 | 6/6 (100%) | 11/24 (46%) | 0.0166 |
| β2M | 8/11 (73%) | 10/19 (53%) | 0.2789 | 5/6 (83%) | 13/24 (54%) | 0.1921 |
| Low expression with ≤1 Abs | 7/11 (64%) | 7/19 (37%) | 0.1563 | 6/6 (100%) | 8/24 (33%) | 0.0034 |
Significant differences are shown in bold.
*Staining with HCA2 could not be evaluated in two patients because of negativity of normal cells.
Abs, antibodies; CR, complete response; HLA, human leukocyte antigen; β2M, β2-microglobulin; PD, progressive disease; PR, partial response; SD, stable disease.